Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Kura Oncology is bringing Kyowa Kirin on board as a global development and commercialization partner for ziftomenib, a Phase 3 selective menin inhibitor…
Kura Oncology has signed a global collaboration with Kyowa Kirin worth up to $1.5 billion for ziftomenib, its lead menin inhibitor in Phase 3 development for…
FDA granted full approval of KOMZIFTI (ziftomenib) for adults with R/R NPM1-mutant AML; approval triggers a $135M milestone payment from Kyowa Kirin to Kura.
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin (TSE: 4151) entered a global strategic collaboration and license agreement for ziftomenib, Kura's selective oral menin inhibitor (menin-KMT2A/MLL), announced November 20, 2024 and effective December 2024. Kura received a $330M upfront (held in cash as of 12/31/24) and is eligible for up to $420M in near-term milestones, up to $513M in additional development/regulatory/commercial milestones in hematologic malignancies, and $228M if Kyowa Kirin exercises the Field Expansion Option -- up to $1.491B in aggregate. In the U.S. Kura leads commercialization under a 50/50 profit/loss share; Kyowa Kirin leads ex-U.S. and pays tiered royalties. The asset advanced rapidly post-deal: the FDA granted Priority Review of the ziftomenib NDA in June 2025, and on November 13, 2025 granted full approval of KOMZIFTI (ziftomenib) for adults with relapsed/refractory NPM1-mutant AML -- the first and only once-daily oral menin inhibitor approved in this setting (pivotal KO-MEN-001 / NCT04067336: CR+CRh 21.4% in 112 patients; 600 mg once daily). The approval triggered a $135M milestone payment from Kyowa Kirin to Kura.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Kyowa Kirin Co. Ltd. / Kura Oncology Inc. (this deal) | 2024 | $1.5B | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2024 deals · Hematology deals